VedaBio Appoints Rachel Jones as Chief Commercial Officer

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting

Constructive Bio Secures $58 Million in Series A Financing

Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting

Lightcast Opens Innovation Center in United States to Support Global Expansion of Luminary Early Access Program

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies

VedaBio launches with $40M+ in initial funding for CRISPR-based molecular detection technology

MYTX-011 Is Given FDA Fast Track Designation for cMET Overexpressing NSCLC

Matterworks Announces CEO Appointment and Board Updates

SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics